drugset / Trial / NCT06032026

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

NCT06032026 ↗

Phase 0 Recruiting 70 enrolled University of Pennsylvania
NaSingle-groupOpen-labelDiagnostic

Summary

The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Multiple System Atrophy (MSA). The investigators will compare uptake in people with MSA with people with Parkinson disease (PD) and progressive supranuclear palsy (PSP) as well as healthy volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (not a clinical site), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.

Timeline

Start
2023-07-20
Primary completion
2028-07-31
Completion
2028-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 11C-HY-2-15 Unknown 740 mbq Intravenous

Indications